89
Participants
Start Date
March 16, 2021
Primary Completion Date
June 20, 2025
Study Completion Date
June 24, 2025
Tadalafil 20 MG
Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
Placebo
Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
Vanderbilt University Medical Center, Nashville
Vanderbilt University Medical Center
OTHER